|
Age in years, median (IQR) a
|
48 (41–54)
|
|
Sex, n (%)
| |
|
Female
|
49 (87.5)
|
|
Male
|
7 (12.5)
|
|
a Duration of illness before scan in days, median (IQR)
|
17 (14–25)
|
|
b Study type, n (%)
| |
|
Q SPECT/CT scan
|
47 (83.9)
|
|
VQ SPECT/CT scan
|
9 (16.1)
|
|
b Follow-up study, n (%)
| |
|
None
|
42 (75.0)
|
|
VQ SPECT/CT scan
|
14 (25.0)
|
|
Defects, n (%)
| |
|
No
|
24 (42.9)
|
|
Yes
|
32 (57.1)
|
|
Mosaic attenuation, n (%)
| |
|
No
|
32 (57.1)
|
|
Yes
|
24 (42.9)
|
|
COVID pneumonia, n (%)
| |
|
No
|
32 (57.1)
|
|
Yes
|
24 (42.9)
|
|
b Defects from PE, n (%)
| |
|
No
|
31 (55.4)
|
|
Yes
|
20 (35.7)
|
|
Non-diagnostic
|
5 (8.9)
|
|
b Defects with mosaic attenuation other than PE, n (%)
| |
|
No
|
39 (69.6)
|
|
Yes
|
17 (30.4)
|
|
Defects from pulmonary infiltrates, n (%)
| |
|
No
|
50 (89.3)
|
|
Yes
|
6 (10.7)
|
|
Shunting, n (%)
| |
|
No
|
46 (82.1)
|
|
Yes
|
10 (17.9)
|
